Abstract
ADHD is now the 9th largest segment of the CNS market by sales with growth of
8% year-on-year. Find out more in this chapter of CNS Drug Discoveries.
The value of the ADHD market was US$2.6 billion in 2005 and it is now the 9th
largest segment of the CNS market by sales with growth of 8% year-on-year.
Global sales of ADHD drugs are forecast to reach US$4.3 billion by 2012. This
will be due to greater penetration in the treatment of new patients,
particularly adult ADHD, improvements in patient compliance due to the launch
of new formulations, new non-schedule II drugs and the development of novel
classes of drugs in late-stage clinical trials.
There has been a significant increase in ADHD diagnosis and prescription of
medicine since the early 1990s due to wider understanding of the condition in
the mental health community, increased use of medication and healthcare
coverage and the launch of ADHD-specific drugs (from 2000 onwards). ADHD is
one of the most common psychiatric disorders of childhood and approximately
50% to 70% of children with ADHD will continue to experience symptoms into
adulthood. In 2000, it was estimated that 4-5 million individuals (mainly
children) were diagnosed with ADHD of whom 75-85% were treated with
psychostimulants. Over 8 million adults in the US may exhibit the symptoms of
ADHD, while only an estimated 600,000 are being treated.
Global ADHD market
Approximately 90% of ADHD global sales were derived from the US in 2005, with
the remainder from Europe. This is largely due to a higher diagnosis rate in
paediatrics and availability of drugs for medical reimbursement. Growth in
adult ADHD medications has increased exponentially whilst their use in
children has slowed due to safety concerns. Growth has also been driven by the
launch of new non-stimulant drugs, new patients and the development of new
formulations providing flexibility in dosing and higher patient compliance.
This has helped to offset the impact of generics which are beginning to emerge
on the market.
View Cart
